LIPO (Lipella Pharmaceuticals) Operating Margin %: 0.00% (As of Sep. 2025)


What is Lipella Pharmaceuticals Operating Margin %?

Lipella Pharmaceuticals LIPO +8.43% Operating Margin % is 0.00% as of Sep. 2025. The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Lipella Pharmaceuticals ranks worse than 78.73% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Lipella Pharmaceuticals's Operating Income for the three months ended in Sep. 2025 was $-1.27 Mil. Lipella Pharmaceuticals's Revenue for the three months ended in Sep. 2025 was $0.00 Mil. Therefore, Lipella Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2025 was 0.00%.

The historical rank and industry rank for Lipella Pharmaceuticals's Operating Margin % or its related term are showing as below:

LIPO' s Operating Margin % Range Over the Past 10 Years
Min: -1407.61   Med: -947.95   Max: -5.93
Current: -1009.33


LIPO's Operating Margin % is ranked worse than
78.73% of 945 companies
in the Biotechnology industry
Industry Median: -86.89 vs LIPO: -1009.33

Lipella Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Lipella Pharmaceuticals's Operating Income for the three months ended in Sep. 2025 was $-1.27 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2025 was $-5.41 Mil.


Lipella Pharmaceuticals  (OTCPK:LIPO) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Lipella Pharmaceuticals Operating Margin % Related Terms


Lipella Pharmaceuticals Operating Margin % Historical Data

* Premium members only.

The historical data trend for Lipella Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lipella Pharmaceuticals Operating Margin % Chart

Lipella Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Operating Margin %
-5.93 -739.77 -1,407.61 -1,054.67 -947.95

Lipella Pharmaceuticals Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -270.71 0.00 0.00 0.00

LIPO vs WINT, RMTG, CYTOF: Operating Margin % Comparison

For the Biotechnology subindustry, Lipella Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipella Pharmaceuticals Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Lipella Pharmaceuticals's Operating Margin % falls into.



Lipella Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Lipella Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2024 is calculated as

Operating Margin %=Operating Income (A: Dec. 2024 ) / Revenue (A: Dec. 2024 )
=-5.081 / 0.536
=-947.95 %

Lipella Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2025 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2025 ) / Revenue (Q: Sep. 2025 )
=-1.274 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 0.00% mean?
Lipella Pharmaceuticals (LIPO) has a Operating Margin % of 0.00% as of Sep. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Lipella Pharmaceuticals and its competitors. According to the industry distribution chart, Lipella Pharmaceuticals ranks #744 out of 945 companies in the Biotechnology industry, placing it in the top 78.7%.
Is Lipella Pharmaceuticals' Operating Margin % too high?
Lipella Pharmaceuticals' current Operating Margin % is 0.00%. Based on the distribution chart, Lipella Pharmaceuticals ranks #744 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Lipella Pharmaceuticals' Operating Margin % compare to WINT and RMTG?
According to the Biotechnology industry distribution chart, Lipella Pharmaceuticals ranks #744 out of 945 companies for Operating Margin %. This places Lipella Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Lipella Pharmaceuticals and its competitors. Lipella Pharmaceuticals's current Operating Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.66, compared to a current price of $0.09 — trading 99% below its estimated fair value. The current Operating Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current Operating Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lipella Pharmaceuticals Business Description

Address 7800 Susquehanna Street, Suite 505, Pittsburgh, PA, USA, 15208
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.